FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.
|Articles|September 4, 2014
DHA supplements lower hay fever risk in premature boys (VIDEO)
Michael Banks, MD, discusses a study published in Pediatrics, which concludes that DHA in high doses reduced the risk for hey fever in male toddlers who were born prematurely. Video provided by The Doctor's Channel.
Advertisement
Michael Banks, MD, discusses a study published in
This video is part of the Toddler Fever and Pain Management Resource Center
Video provided by:
Advertisement
Related to this article
Tallie Z. Baram, MD, talks about how adding a measure of childhood unpredictability to ACEs screening may help pediatricians identify children at risk for mental health problems.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
The FDA granted priority review to efzimfotase alfa for HPP in patients aged 2 years and older; a decision is expected in the first half of 2027.
Adolescent VALIANT subgroup data show pegcetacoplan cut proteinuria 75% vs placebo, supporting its expanded pediatric kidney indication.
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, as the first treatment for pediatric MPS IIIA (Sanfilippo syndrome type A).
Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.
Melissa Wallach, MD, FAAP, discusses what pediatricians should know about updated screening, supplementation, and treatment recommendations for iron deficiency.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
FDA grants priority review to efzimfotase alfa for hypophosphatasia in patients aged 2 years and older
3
FDA approves levacetylleucine as first treatment for ataxia in ataxia-telangiectasia
4
Pegcetacoplan reduces proteinuria, stabilizes kidney function in adolescents with C3G and IC-MPGN
5